Exempting Rare Disease Drugs From Medicare Price Pilot Would Eliminate Massive Savings

New research reveals that excluding rare disease therapies from Medicare's drug-pricing pilot program would significantly reduce potential savings for patients and the healthcare system. The analysis demonstrates that rare disease medications, while treating smaller populations, represent a substantial portion of overall drug costs that could be controlled through the pricing initiative. This finding has important implications for policy decisions about which medications should be included in efforts to make prescriptions more affordable. Healthcare advocates are concerned that exemptions could undermine the effectiveness of price negotiations and limit relief for patients struggling with high medication costs.